Roth Capital Positive on Heat Biologics (HTBX) as HS-110 Combo Phase 1b Enrollment Resumes

September 14, 2016 12:26 PM EDT
Get Alerts HTBX Hot Sheet
Price: $0.90 -5.26%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 22 | New: 54
Trade HTBX Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Roth Capital affirms Heat Biologics (Nasdaq: HTBX) at Buy with a price target of $2.75 after the company announced resumption enrollment in its Phase 1b trial evaluating HS-110 in combination with nivolumab (Opdivo).

Analyst Joseph Pantginis commented today, We believe that trial resumption for HS-110 in combination with nivolumab for NSCLC signals a positive view of the data showing an increase in CD8+ T cells in biopsy samples that derived from tumors originally classified as cold. As cold tumors tend to be less responsive to checkpoint inhibitor monotherapy, we believe that if HS-110 increases T cell infiltration it may sensitize the tumors to other therapies resulting in positive outcomes. We hope to get a better perspective on T cell tumor infiltration when HTBX releases additional data, as topline data for the patients to be enrolled in the NSCLC trial are expected within the next twelve months. In addition, HTBX expects to report topline 6-month data for the original eight patients in 4Q16.

For an analyst ratings summary and ratings history on Heat Biologics click here. For more ratings news on Heat Biologics click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Roth Capital, S1

Add Your Comment